HRP20241318T1 - Novi spojevi - Google Patents

Novi spojevi Download PDF

Info

Publication number
HRP20241318T1
HRP20241318T1 HRP20241318TT HRP20241318T HRP20241318T1 HR P20241318 T1 HRP20241318 T1 HR P20241318T1 HR P20241318T T HRP20241318T T HR P20241318TT HR P20241318 T HRP20241318 T HR P20241318T HR P20241318 T1 HRP20241318 T1 HR P20241318T1
Authority
HR
Croatia
Prior art keywords
benzofuran
dione
pharmaceutically acceptable
ethyl
compound
Prior art date
Application number
HRP20241318TT
Other languages
English (en)
Croatian (hr)
Inventor
Giuseppe Alvaro
Agostino Marasco
Original Assignee
Autifony Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Limited filed Critical Autifony Therapeutics Limited
Publication of HRP20241318T1 publication Critical patent/HRP20241318T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20241318TT 2018-10-16 2019-10-16 Novi spojevi HRP20241318T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18200626 2018-10-16
EP19790048.3A EP3867247B1 (en) 2018-10-16 2019-10-16 Novel compounds
PCT/GB2019/052937 WO2020079422A1 (en) 2018-10-16 2019-10-16 Novel compounds

Publications (1)

Publication Number Publication Date
HRP20241318T1 true HRP20241318T1 (hr) 2024-12-20

Family

ID=63878368

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241318TT HRP20241318T1 (hr) 2018-10-16 2019-10-16 Novi spojevi

Country Status (21)

Country Link
US (1) US20250304564A1 (cg-RX-API-DMAC7.html)
EP (1) EP3867247B1 (cg-RX-API-DMAC7.html)
JP (1) JP7465868B2 (cg-RX-API-DMAC7.html)
KR (1) KR102854594B1 (cg-RX-API-DMAC7.html)
AR (1) AR116713A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019360017B9 (cg-RX-API-DMAC7.html)
BR (1) BR112021006940A2 (cg-RX-API-DMAC7.html)
DK (1) DK3867247T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988842T3 (cg-RX-API-DMAC7.html)
FI (1) FI3867247T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241318T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068686T2 (cg-RX-API-DMAC7.html)
IL (1) IL282096B2 (cg-RX-API-DMAC7.html)
LT (1) LT3867247T (cg-RX-API-DMAC7.html)
MX (1) MX2021004386A (cg-RX-API-DMAC7.html)
PL (1) PL3867247T3 (cg-RX-API-DMAC7.html)
PT (1) PT3867247T (cg-RX-API-DMAC7.html)
SI (1) SI3867247T1 (cg-RX-API-DMAC7.html)
TW (1) TWI827706B (cg-RX-API-DMAC7.html)
WO (1) WO2020079422A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101487B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
BR112022013339A2 (pt) * 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
EP4384165B1 (en) * 2021-08-09 2025-07-09 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators for use in autism spectrum disorders
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
PL2788339T3 (pl) 2011-12-06 2016-09-30 Pochodne hydantoiny przydatne jako inhibitory KV3
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Kv3阻害剤としてのヒダントイン誘導体
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels

Also Published As

Publication number Publication date
SI3867247T1 (sl) 2024-11-29
FI3867247T3 (fi) 2024-10-30
TWI827706B (zh) 2024-01-01
ES2988842T3 (es) 2024-11-21
HUE068686T2 (hu) 2025-01-28
JP2022505143A (ja) 2022-01-14
TW202035394A (zh) 2020-10-01
WO2020079422A1 (en) 2020-04-23
AU2019360017B2 (en) 2025-03-06
DK3867247T3 (da) 2024-09-16
IL282096A (en) 2021-05-31
KR20210076081A (ko) 2021-06-23
IL282096B1 (en) 2024-03-01
EP3867247A1 (en) 2021-08-25
MX2021004386A (es) 2021-06-04
PL3867247T3 (pl) 2024-12-09
PT3867247T (pt) 2024-09-17
AR116713A1 (es) 2021-06-02
AU2019360017A1 (en) 2021-04-01
EP3867247B1 (en) 2024-07-24
LT3867247T (lt) 2024-11-11
BR112021006940A2 (pt) 2021-07-13
JP7465868B2 (ja) 2024-04-11
AU2019360017B9 (en) 2025-03-27
KR102854594B1 (ko) 2025-09-02
US20250304564A1 (en) 2025-10-02
IL282096B2 (en) 2024-07-01
ZA202101487B (en) 2024-05-30

Similar Documents

Publication Publication Date Title
JP2022505143A5 (cg-RX-API-DMAC7.html)
JP2013544873A5 (cg-RX-API-DMAC7.html)
JP2016145215A5 (cg-RX-API-DMAC7.html)
JP2014516073A5 (cg-RX-API-DMAC7.html)
NZ603427A (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
HRP20240497T1 (hr) Modulatori kv3 kanala za liječenje boli
AU2011240131B2 (en) Arylethynyl derivatives
JP2019502696A5 (cg-RX-API-DMAC7.html)
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
HRP20151018T1 (hr) Pirolopiridini kao inhibitori kinaze
US20110077280A1 (en) Hepatitis C Virus Inhibitors
HRP20190947T1 (hr) Heterociklički spoj
US20110237636A1 (en) Hepatitis C Virus Inhibitors
MY192029A (en) 6, 7-dihydropyrazolo [1,5-()]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
HRP20160641T1 (hr) Fuzionirani triciklički spojevi kao inhibitori raf kinaze
JP2013513564A5 (cg-RX-API-DMAC7.html)
HRP20130095T1 (hr) Spojevi triazola koji moduliraju aktivnost hsp90
CA2315735A1 (en) Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
JP2016511258A5 (cg-RX-API-DMAC7.html)
RU2014124640A (ru) Производные аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
JP2015502951A5 (cg-RX-API-DMAC7.html)
JP2019506367A5 (cg-RX-API-DMAC7.html)
JP2023539985A5 (cg-RX-API-DMAC7.html)
JP2017523223A5 (cg-RX-API-DMAC7.html)
HRP20181017T1 (hr) Heterociklični spojevi i postupci uporabe